Lupus & antiphospholipid syndrome
Clinical efficacy of centrifugal-membranous hybrid double filtration plasmapheresis and membranous double filtration plasmapheresis on severe lupus nephritis
Authors' conclusion
Although there was no significant difference in clinical efficacy between C/M hybrid DFPP and M DFPP on severe LN, the risk of bleeding complications was significantly lower in the C/M hybrid DFPP group.
Study context
- Population
- Patients diagnosed with severe lupus nephritis (LN) who had received DFPP treatment181 DFPPs performed
- Participants
- 70 patients
- Exposure
- C/M hybrid DFPP vs M DFPP
- C/M hybrid DFPPn = 51
- M DFPPn = 19reference
- Outcome
- Clinical efficacy (ANA, anti-dsDNA titer, urinary protein, serum creatinine, hemoglobin)
- Follow-up
- After DFPP treatment and at third month after treatment
Main finding
As reported in the abstract
- ANA, anti-dsDNA titer, quantitative urinary protein and serum creatinine decreased significantly and hemoglobin increased significantly after DFPP treatment and at 3rd month
- No significant difference in clinical efficacy between C/M hybrid DFPP and M DFPP
Observational data: associations, not effects.
Safety
Events
- Bleeding complications — M DFPP
- 2
- Perioral numbness — C/M hybrid DFPP
- 4
Bleeding complications
- Risk of bleeding complications significantly lower in C/M hybrid DFPP
Original publication
Clinical efficacy of centrifugal-membranous hybrid double filtration plasmapheresis and membranous double filtration plasmapheresis on severe lupus nephritis. Lupus. Published 24 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →